- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Consent agreement moves Nexium alternative closer to FDA approval
A federal court in New Jersey has entered a consent judgment regarding the patent infringement litigation between Hanmi Pharmaceuticals (Seoul, Korea) and AstraZeneca (London).
A federal court in New Jersey has entered a consent judgment regarding the patent infringement litigation between Hanmi Pharmaceuticals (Seoul, Korea) and AstraZeneca (London).
In February of 2011, AstraZeneca filed suit alleging that Hanmi’s proposal to market esomeprazole strontium delayed release capsules infringed two of its patents involving its heartburn drug Nexium.
The consent judgment stipulates that Hanmi acknowledges that AstraZeneca’s two asserted patents are enforceable and valid, and that the Hanmi product does not infringe on them--based on a court ruling issued on December 12, 2013. AstraZeneca has reserved its right to appeal that ruling.
FDA tentatively approved Hanmi’s product on April 30, 2013, and the company anticipates receiving final approval soon. Hanmi’s product would be the first generic product commercialized in the United States that contains the active moiety esomeprazole. Amneal Pharmaceuticals will partner with Hanmi to market the product following FDA approval.
Two Lawsuits Allege Iowa Medicaid Did Not Provide Proper Mental Health Care
May 25th 2023Iowa's Department of Health and Human Services, which manages the two health insurers that delivered care to adults and children in the state’s Medicaid program last year, was alleged to provide inadequate mental and behavioral health care to children on Medicaid.
Sulbactam-Durlobactam for Bacterial Pneumonia Gets FDA Approval
May 24th 2023The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
